Microhomologies and topoisomerase II consensus sequences identified near the breakpoint junctions of the recurrent t(7;21)(p22;q22) translocation in acute myeloid leukemia

Genes Chromosomes and Cancer

Volumn 50, Issue 4, 2011, Pages 228-238

  Giguère, Amélie ^a,b   Hébert, Josée ^a,b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BIOINFORMATICS; CASE REPORT; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; CONSENSUS SEQUENCE; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; KARYOTYPING; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

ADULT; ANTIGENS, NEOPLASM; BASE SEQUENCE; CHROMOSOME BREAKPOINTS; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 7; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MUTANT CHIMERIC PROTEINS; THIOLESTER HYDROLASES; TRANSLOCATION, GENETIC;

EID: 79851472433     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20848     Document Type: Article

References (53)

1. Aplan PD. 2006a. Causes of oncogenic chromosomal translocation. Trends Genet 22: 46-55.
2. Aplan PD. 2006b. Chromosomal translocations involving the MLL gene: Molecular mechanisms. DNA Repair (Amst) 5: 1265-1272.
3. Aplan PD, Chervinsky DS, Stanulla M, Burhans WC. 1996. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 87: 2649-2658.
4. Chinen Y, Taki T, Nishida K, Shimizu D, Okuda T, Yoshida N, Kobayashi C, Koike K, Tsuchida M, Hayashi Y, Taniwaki M. 2008. Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA. Oncogene 27: 2249-2256.
5. Daviet L, Colland F. 2008. Targeting ubiquitin specific proteases for drug discovery. Biochimie 90: 270-283.
6. De Braekeleer E, Ferec C, De Braekeleer M. 2009. RUNX1 translocations in malignant hemopathies. Anticancer Res 29: 1031-1037.
7. Felix CA, Kolaris CP, Osheroff N. 2006. Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst) 5: 1093-1108.
8. Foster N, Paulsson K, Sales M, Cunningham J, Groves M, O'Connor N, Begum S, Stubbs T, McMullan DJ, Griffiths M, Pratt N, Tauro S. 2010. Molecular characterisation of a recurrent, semi-cryptic RUNX1 translocation t(7;21) in myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol 148: 938-943.
9. Frankfurt O, Licht JD, Tallman MS. 2007. Molecular characterization of acute myeloid leukemia and its impact on treatment. Curr Opin Oncol 19: 635-649.
10. Gelsi-Boyer V, Trouplin V, Adelaide J, Aceto N, Remy V, Pinson S, Houdayer C, Arnoulet C, Sainty D, Bentires-Alj M, Olschwang S, Vey N, Mozziconacci MJ, Birnbaum D, Chaffanet M. 2008. Genome profiling of chronic myelomonocytic leukemia: Frequent alterations of RAS and RUNX1 genes. BMC Cancer 8: 299.
11. Guidez F, Petrie K, Ford AM, Lu H, Bennett CA, MacGregor A, Hannemann J, Ito Y, Ghysdael J, Greaves M, Wiedemann LM, Zelent A. 2000. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood 96: 2557-2561.
12. Hoeller D, Dikic I. 2009. Targeting the ubiquitin system in cancer therapy. Nature 458: 438-444.
13. International Standing Committee on Human Cytogenetic Nomenclature, Mitelman F. 1995. ISCN 1995: An international system for human cytogenetic nomenclature (1995): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, USA, October 9-13, 1994. Basel: Karger.
14. Izutsu K, Kurokawa M, Imai Y, Ichikawa M, Asai T, Maki K, Mitani K, Hirai H. 2002. The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP. Oncogene 21: 2695-2703.
15. Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, Shih LY. 2009. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 23: 1426-1431.
16. Kwok C, Zeisig BB, Qiu J, Dong S, So CW. 2009. Transforming activity of AML1-ETO is independent of CBFβ and ETO interaction but requires formation of homo-oligomeric complexes. Proc Natl Acad Sci USA 106: 2853-2858.
17. Langer T, Metzler M, Reinhardt D, Viehmann S, Borkhardt A, Reichel M, Stanulla M, Schrappe M, Creutzig U, Ritter J, Leis T, Jacobs U, Harbott J, Beck JD, Rascher W, Repp R. 2003. Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: Almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. Genes Chromosomes Cancer 36: 393-401.
18. Lovett BD, Lo Nigro L, Rappaport EF, Blair IA, Osheroff N, Zheng N, Megonigal MD, Williams WR, Nowell PC, Felix CA. 2001. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc Natl Acad Sci USA 98: 9802-9807.
19. Maki K, Yamagata T, Mitani K. 2008. Role of the RUNX1-EVI1 fusion gene in leukemogenesis. Cancer Sci 99: 1878-1883.
20. Mikhail FM, Sinha KK, Saunthararajah Y, Nucifora G. 2006. Normal and transforming functions of RUNX1: A perspective. J Cell Physiol 207: 582-593.
21. Mitelman F, Johansson B, Mertens F. 2007. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7: 233-245.
22. Morrow M, Samanta A, Kioussis D, Brady HJ, Williams O. 2007. TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL. Oncogene 26: 4404-4414.
23. Mrozek K, Bloomfield CD. 2006. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 169-177.
24. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R. 2005. A genomic and functional inventory of deubiquitinating enzymes. Cell 123: 773-786.
25. Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD. 1994. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 β/CBF β proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol 14: 5558-5568.
26. Oliveira AM, Perez-Atayde AR, Inwards CY, Medeiros F, Derr V, Hsi BL, Gebhardt MC, Rosenberg AE, Fletcher JA. 2004. USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol 165: 1773-1780.
27. Oliveira AM, Perez-Atayde AR, Dal Cin P, Gebhardt MC, Chen CJ, Neff JR, Demetri GD, Rosenberg AE, Bridge JA, Fletcher JA. 2005. Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene 24: 3419-3426.
28. Osato M. 2004. Point mutations in the RUNX1/AML1 gene: Another actor in RUNX leukemia. Oncogene 23: 4284-4296.
29. Panagopoulos I, Mertens F, Lofvenberg R, Mandahl N. 2008. Fusion of the COL1A1 and USP6 genes in a benign bone tumor. Cancer Genet Cytogenet 180: 70-73.
30. Paulsson K, Bekassy AN, Olofsson T, Mitelman F, Johansson B, Panagopoulos I. 2006. A novel and cytogenetically cryptic t(7;21)(p22;q22) in acute myeloid leukemia results in fusion of RUNX1 with the ubiquitin-specific protease gene USP42. Leukemia 20: 224-229.
31. Peterson LF, Zhang DE. 2004. The 8;21 translocation in leukemogenesis. Oncogene 23: 4255-4262.
32. Poland KS, Shardy DL, Azim M, Naeem R, Krance RA, Dreyer ZE, Neeley ES, Zhang N, Qiu YH, Kornblau SM, Plon SE. 2009. Overexpression of ZNF342 by juxtaposition with MPO promoter/enhancer in the novel translocation t(17;19)(q23; q13.32) in pediatric acute myeloid leukemia and analysis of ZNF342 expression in leukemia. Genes Chromosomes Cancer 48: 480-489.
33. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, Moll R, Elledge SJ, Eilers M. 2007. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 9: 765-774.
34. Quesada V, Diaz-Perales A, Gutierrez-Fernandez A, Garabaya C, Cal S, Lopez-Otin C. 2004. Cloning and enzymatic analysis of 22 novel human ubiquitin-specific proteases. Biochem Biophys Res Commun 314: 54-62.
35. Raffini LJ, Slater DJ, Rappaport EF, Lo Nigro L, Cheung NK, Biegel JA, Nowell PC, Lange BJ, Felix CA. 2002. Panhandle and reverse-panhandle PCR enable cloning of der(11) and der (other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6. Proc Natl Acad Sci USA 99: 4568-4573.
36. Reiter A, Saussele S, Grimwade D, Wiemels JL, Segal MR, Lafage-Pochitaloff M, Walz C, Weisser A, Hochhaus A, Willer A, Reichert A, Buchner T, Lengfelder E, Hehlmann R, Cross NC. 2003. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes Cancer 36: 175-188.
37. Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, Geffroy S, Lai JL, Nicolini FE, Preudhomme C. 2008. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood 111: 3735-3741.
38. Roulston D, Espinosa R, III, Nucifora G, Larson RA, Le Beau MM, Rowley JD. 1998. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: Association with prior therapy. Blood 92: 2879-2885.
39. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory. 3 v. pA8.9
40. Spitzner JR, Muller MT. 1988. A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res 16: 5533-5556.
41. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerod A, Russnes HE, Foekens JA, Reis-Filho JS, van 't Veer L, Richardson AL, Borresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR. 2009. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462: 1005-1010.
42. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. World Health Organization. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: International Agency for Research on Cancer. 439 p.
43. Takahashi A, Satake M, Yamaguchi-Iwai Y, Bae SC, Lu J, Maruyama M, Zhang YW, Oka H, Arai N, Arai K, Ito Y. 1995. Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2. Blood 86: 607-616.
44. Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, Huang CF, Lee FY, Liu MC, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Lin LI, Tien HF. 2009. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: Prognostic implication and interaction with other gene alterations. Blood 114: 5352-5361.
45. von Goessel H, Jacobs U, Semper S, Krumbholz M, Langer T, Keller T, Schrauder A, van der Velden VH, van Dongen JJ, Harbott J, Panzer-Grumayer ER, Schrappe M, Rascher W, Metzler M. 2009. Cluster analysis of genomic ETV6-RUNX1 (TEL-AML1) fusion sites in childhood acute lymphoblastic leukemia. Leuk Res 33: 1082-1088.
46. Weinstock DM, Richardson CA, Elliott B, Jasin M. 2006. Modeling oncogenic translocations: Distinct roles for double-strand break repair pathways in translocation formation in mammalian cells. DNA Repair (Amst) 5: 1065-1074.
47. Whitmarsh RJ, Saginario C, Zhuo Y, Hilgenfeld E, Rappaport EF, Megonigal MD, Carroll M, Liu M, Osheroff N, Cheung NK, Slater DJ, Ried T, Knutsen T, Blair IA, Felix CA. 2003. Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Oncogene 22: 8448-8459.
48. Xiao Z, Greaves MF, Buffler P, Smith MT, Segal MR, Dicks BM, Wiencke JK, Wiemels JL. 2001. Molecular characterization of genomic AML1-ETO fusions in childhood leukemia. Leukemia 15: 1906-1913.
49. Yan M, Ahn EY, Hiebert SW, Zhang DE. 2009. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. Blood 113: 883-886.
50. Ye Y, Pringle LM, Lau AW, Riquelme DN, Wang H, Jiang T, Lev D, Welman A, Blobel GA, Oliveira AM, Chou MM. 2010. TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-κB. Oncogene 29: 3619-3629.
51. Zhang DE, Fujioka K, Hetherington CJ, Shapiro LH, Chen HM, Look AT, Tenen DG. 1994. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol 14: 8085-8095.
52. Zhang Y, Rowley JD. 2006. Chromatin structural elements and chromosomal translocations in leukemia. DNA Repair (Amst) 5: 1282-1297.
53. Zhang Y, Strissel P, Strick R, Chen J, Nucifora G, Le Beau MM, Larson RA, Rowley JD. 2002. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci USA 99: 3070-3075.